司美格鲁肽全球热销催生百亿市场:国内30+企业激战GLP-1赛道,2025年产能格局全解析

摩熵医药
Dec 02, 2025

近年来,随着GLP-1受体激动剂在全球减重与糖尿病治疗市场的持续火热,司美格鲁肽(Semaglutide)作为其中的明星分子,市场需求呈爆发式增长。据财报数据显示,诺和诺德司美格鲁肽系列产品(如Ozempic®和Wegovy®)在2023年的全球销售额已突破200亿美元大关,2024年司美格鲁肽销售额2018.49亿丹麦克朗,接近300亿美元,同比增长近40%,2025年Q3数据显示Ozempic...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10